SANUWAVE Health Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced the European launch of its orthoPACE™ device for orthopedic, trauma and sports medicine indications.

The orthoPACE integrates SANUWAVE’s proprietary Pulsed Acoustic Cellular Expression (PACE™) extracorporeal shock wave technology (ESWT) used to treat a variety of chronic and acute conditions in hard and soft tissue.

Christopher M. Cashman, president and CEO of SANUWAVE, said orthoPACE has received positive feedback from healthcare professionals and distributors in the European market, and that the company anticipates further growth and awareness in the upcoming year.

“The orthoPACE device offers significant enhancements to our past successful legacy orthopedic products, including the Ossatron®. The orthoPACE offers the best aspects and the same solid clinical efficacy, along with new features and expanded treatment potential. The orthoPACE has been well received by our European distributors and clinicians, and we expect the product to continue to gain visibility and momentum in 2010,” Chasman stated in the press release.

The orthoPACE emits electrohydraulic shock waves that activate biological signaling and angiogenic responses that help restore the body’s normal healing and regeneration processes. The technology is 100% non-invasive, eliminating the risk of infection or scarring.

For more information visit www.sanuwave.com